Spero Therapeutics, Inc.SPRONASDAQ
Loading
Operating cash flow minus capital expenditures
Latest
$-27.67M
↑ 18% vs avg
Percentile
P60
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-33.92M
Historical baseline
| Period | Value | YoY Change |
|---|---|---|
| TTM | $-27.67M | -18.0% |
| 2024 | $-23.44M | +28.9% |
| 2023 | $-32.99M | -326.8% |
| 2022 | $-7.73M | - |
| 2021 | $0.00 | +100.0% |
| 2020 | $-86.03M | -70.9% |
| 2019 | $-50.33M | -19.7% |
| 2018 | $-42.06M | -7.5% |
| 2017 | $-39.14M | -31.4% |
| 2016 | $-29.79M | - |